MKMridula Krishnan

Mridula Krishnan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mridula Krishnan has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    EGFR Signaling in Colorectal Cancer Metastasis: Molecular Mechanisms and Targeted Therapeutic Strategies

    by Premila Leiphrakpam, Senthil J. Rajappa, Mridula Krishnan, Rishi Batra, Chandrakanth Are

    Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide, with metastatic colorectal cancer (mCRC) accounting for most CRC-associated deaths. Despite advances in systemic therapy, mCRC remains associated with poor prognosis because of its molecular heterogeneity, metastatic potential, and the emergence of therapeutic resistance. Improved understanding of the molecular landscape of mCRC has enabled biomarker-driven treatment strategies that have advanced precision oncology. Among the key signaling pathways involved in mCRC, the epidermal growth factor receptor (EGFR) pathway plays a central role in tumor progression and metastasis. EGFR activation triggers the RAS-RAF-MEK-ERK (rat sarcoma-rapidly accelerated fibrosarcoma-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase) and PI3K-AKT-mTOR (phosphoinositide 3-kinase–protein kinase B–mechanistic target of rapamycin) signaling cascades, promoting cellular proliferation, survival, migration, invasion, angiogenesis, and therapeutic resistance. Genetic alterations involving KRAS (kirsten rat sarcoma viral oncogene homolog), NRAS (neuroblastoma rat sarcoma viral oncogene homolog), BRAF (B-Raf proto-oncogene, serine/threonine kinase), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), HER2 (human epidermal growth factor receptor 2), and PTEN (phosphatase and tensin homolog) frequently dysregulate these pathways and serve as predictive biomarkers for targeted therapy. Anti-EGFR monoclonal antibodies have transformed the treatment landscape of mCRC. However, their clinical benefit is frequently limited by intrinsic and acquired resistance mechanisms driven by molecular alterations, pathway redundancy, compensatory signaling, and tumor heterogeneity. This review examines the role of EGFR signaling in CRC metastasis, the molecular alterations affecting EGFR-associated pathways, and the evolving landscape of EGFR-directed and pathway-focused targeted therapies in mCRC.

  • Open Access

    Long-Term Survival Rates and Treatment Trends of Burkitt Lymphoma in Patients with HIV—A National Cancer Database (NCDB) Study

    by Clare M. Wieland, Ashley M. Tuin, Elizabeth J. Dort, Alexander G. Hall, Mridula Krishnan, Manasa Velagapudi

    Background: Burkitt lymphoma (BL) accounts for 10–35% of AIDS-defining lymphoma in people with HIV (PWH). Previous research consisting of smaller cohorts has shown decreased survival for HIV-associated BL. This study aims to compare overall mortality in BL patients with and without HIV, while investigating impact of treatment modalities in HIV-associated BL. Methods: Using the 2004–2019 NCDB, we identified 4312 patients with stage 3 or 4 BL who had a known HIV status and received either chemotherapy alone or chemotherapy and immunotherapy. Time to death was evaluated using Kaplan–Meier survival estimates. Risk of death was evaluated using an extended multivariable Cox model adjusted for multiple factors and with a Heaviside function for HIV status by time period (0–3 month vs. 3–60 month). Results: Of the 4312 patients included, 1514 (35%) had HIV. For months 0–3 from time of diagnosis, HIV status was not associated with a statistically significant increase in risk of death (HR = 1.04, 95% CI: 0.86, 1.26, p = 0.6648). From month 3to 60, positive HIV status was associated with a 55% increase in risk of death compared to those without HIV (95% CI: 1.38, 1.75, p < 0.0001). Further, this difference in hazard rates (0–3 vs. 3–60) was statistically significant (HR = 1.49, 95% CI: 1.22–1.82, p < 0.001). Conclusions: There is an increased mortality rate from months 3 to 60 in BL patients with HIV compared to patients without HIV. Additionally, risk of death in the first 3 months is significantly decreased by 45% in patients with HIV treated with combination chemotherapy and immunotherapy compared to patients without HIV receiving combination chemotherapy and immunotherapy, providing valuable clinical insight into treatment decision making in the care of HIV-associated BL.


  • The Evolving Landscape of Pancreatic Cancer

    by Mridula Krishnan

    Commentary on evolving landscape of pancreatic cancer #JOP


  • Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors

    by Mridula Krishnan, Pooja Kasinath, Robin High, Fang Yu, Benjamin A. Teply

    PURPOSE: Clinical trials, which led to the approval of immune checkpoint inhibitors (ICI), have been almost exclusively performed in patients with good Eastern Cooperative Oncology Group performance status (ECOG PS of 0-1). However, ICI remains an attractive option for patients with advanced tumors and poor PS. We hypothesized that patients with ECOG PS ≥ 2 would have worse outcomes with ICI. METHODS: We retrospectively identified patients with advanced solid tumors who were treated with ICI at our institution. The log-rank test compared the survival among patients with different ECOG PS. We used a proportional hazards model to assess association between ECOG PS and overall survival (OS) with adjustment for covariates including age, sex, malignancy type, time from advance disease diagnosis, and line of therapy. We compared overall response rates between groups with Pearson chi-square exact test. We also analyzed in-hospital mortality and hospice referral rates. RESULTS: We identified 257 patients treated with ICI. One hundred eighty-two patients had ECOG PS 0-1, and 75 had ECOG PS ≥ 2. The median overall survival was 12.6 months for the ECOG PS 0-1 group compared with 3.1 months for the ECOG PS ≥ 2 group ( P < .001). The overall response rate for patients with ECOG PS 0-1 was 23% compared with 8% for those with poor PS ( P = .005). Patients with poor PS treated with ICI had similar hospice referral rates (67% for ECOG PS ≥ 2 v 61.9% for ECOG PS 0-1, P = .50) but were more likely to have in-hospital death as compared with the good PS group (28.6% v 15.1%, P = .035). CONCLUSION: Despite the appeal of ICI in patients with advanced malignancy and poor PS, outcomes in this cohort were poor. Prospective trials defining the activity and role of ICI in poor PS are urgently needed.


  • Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma

    by Mridula Krishnan, R. Gregory Bociek, Michelle Fanale, Swaminathan P. Iyer, Mary Jo Lechowicz, Philip J. Bierman, James O. Armitage, Matthew Lunning, Avyakta Kallam, Julie M. Vose

    Peripheral T-cell lymphomas (PTCL) are a unique subset of lymphomas with a poor prognosis due to limited treatment options. We performed a phase 1 study of carfilzomib in patients with relapsed/refractory PTCL to determine the safety profile and the maximum tolerated dose (MTD) of this agent. The study was a classical 3 + 3 phase 1 design with intra-patient dose escalation allowed beginning on day 8 of cycle 1 and subsequently. Dose-limiting toxicity (DLT) was defined as the occurrence of any grade 3/4 adverse event. Carfilzomib was given on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Fifteen patients were enrolled from 3 centers. The median age of patients was 62. The median number of prior therapies for subjects on this trial was five. The MTD of carfilzomib was 36 mg/m2. Dose-limiting toxicities included anemia and sepsis. Serious adverse events were seen in 45% of patients. Single-agent carfilzomib leads to a complete response in one patient and a partial response in one patient. Overall, the drug was reasonably tolerated for a heavily pretreated population, but the limited response rate and short duration of response demonstrate a lack of promise for carfilzomib as a single agent in this patient population.


  • The role of targeted therapy in thymic carcinoma

    by Mridula Krishnan, Apar K Ganti

    Thymic carcinoma is a rare entity and can be distinguished from benign thymomas by their aggressive nature and poor prognosis. The National Comprehensive Cancer Network guidelines recommend resection followed by adjuvant platinum-based chemotherapy for resectable tumors. However, the outcomes for metastatic or relapsed thymic carcinomas are poor with no regimen showing a consistent benefit. Moreover, the relative rarity of these tumors makes clinical trials difficult. Molecular analysis of thymomas shows a high incidence of genetic mutations and targeted therapy holds promise. We will briefly outline and review the current role of targeted therapy in thymic cancer.


  • Open Access

    Adult Onset Henoch-Schonlein Purpura and Intussusception: A Rare Presentation

    by Mridula Krishnan, Joseph Nahas

    We present an unusual case of a young 26-year-old male who was diagnosed with Henoch-Schonlein Purpura (HSP). Initial presentation was primarily mild gastrointestinal symptoms, which progressed to a life threatening intussusception and subsequently resolved with prompt glucocorticoid use rather than typical surgical intervention. Of importance, the patient’s initial gastrointestinal symptoms without associated skin manifestations made the diagnosis difficult. In conclusion, it is important to recognize uncommon presentations of HSP as it may lead to life threatening complications and surgical intervention may be avoided with prompt treatment.